July 8, 2020 / 11:40 AM / a month ago

BRIEF-Abeona Therapeutics Reinitiates Enrollment In EB-101 Pivotal Phase 3 Viital™ Study In RDEB After Covid-19 Related Pause

July 8 (Reuters) - Abeona Therapeutics Inc:

* ABEONA THERAPEUTICS REINITIATES ENROLLMENT IN EB-101 PIVOTAL PHASE 3 VIITAL™ STUDY IN RDEB AFTER COVID-19 RELATED PAUSE AND ANNOUNCES PROGRESS IN PATIENT ENROLLMENT IN MPS III STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below